Phase II, safety and immunogenicity of razi cov Pars (RCP) sars cov-2 vaccine in adults aged 18–70 Years; A randomized, double-blind clinical trial
Background This study explores the safety and immunogenicity of the Razi-Cov-Pars (RCP)
SARS Cov-2 recombinant spike protein vaccine. Method In a randomized, double-blind …
SARS Cov-2 recombinant spike protein vaccine. Method In a randomized, double-blind …
CHO cells for virus-like particle and subunit vaccine manufacturing
ZV Sanchez-Martinez, SP Alpuche-Lazcano, M Stuible… - Vaccine, 2024 - Elsevier
Abstract Chinese Hamster Ovary (CHO) cells, employed primarily for manufacturing
monoclonal antibodies and other recombinant protein (r-protein) therapeutics, are emerging …
monoclonal antibodies and other recombinant protein (r-protein) therapeutics, are emerging …
Immunogenicity and safety of a combined intramuscular/intranasal recombinant spike protein COVID-19 vaccine (RCP) in healthy adults aged 18 to 55 years old: a …
MS Dodaran, SR Banihashemi, A Es-Haghi… - Vaccines, 2023 - mdpi.com
Objectives: This study aimed to determine the safety and immunogenicity of a combined
intramuscular/intranasal recombinant spike protein COVID-19 vaccine (RCP). Methods: We …
intramuscular/intranasal recombinant spike protein COVID-19 vaccine (RCP). Methods: We …
Reverse vaccinology and immunoinformatic approach for designing a bivalent vaccine candidate against hepatitis A and hepatitis B viruses
N Ahmadi, M Aghasadeghi, M Hamidi-Fard… - Molecular …, 2023 - Springer
Hepatitis A and B are two crucial viral infections that still dramatically affect public health
worldwide. Hepatitis A Virus (HAV) is the main cause of acute hepatitis, whereas Hepatitis B …
worldwide. Hepatitis A Virus (HAV) is the main cause of acute hepatitis, whereas Hepatitis B …
Immunogenicity and safety of RAZI recombinant spike protein vaccine (RCP) as a booster dose after priming with BBIBP-CorV: a parallel two groups, randomized …
Background The immunity induced by primary vaccination is effective against COVID-19;
however, booster vaccines are needed to maintain vaccine-induced immunity and improve …
however, booster vaccines are needed to maintain vaccine-induced immunity and improve …
[HTML][HTML] Emergence of the SARS-CoV-2 Omicron variant: Current treatments and vaccines for COVID-19
V Vidian, V Litanto, SNA Christy… - … and Hypothesis in …, 2023 - xiahepublishing.com
The world is now in the third year of the COVID-19 pandemic. As such, enormous volumes of
virological, immunological, and epidemiological knowledge pertaining to the SARS-CoV-2 …
virological, immunological, and epidemiological knowledge pertaining to the SARS-CoV-2 …
Production and Characterization of Recombinant Multi-Epitope G Glycoprotein of Rabies Virus
M Gasmi, Z Rahma, RWH Williams-Hooker… - Medical and …, 2023 - pharmacoj.com
Background: Therapeutic proteins have gained increasing interest in research and
development for treatments and vaccines against numerous diseases in recent years. This …
development for treatments and vaccines against numerous diseases in recent years. This …